MACK Stock Overview
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Merrimack Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.68 |
| 52 Week High | US$15.89 |
| 52 Week Low | US$11.53 |
| Beta | 1.43 |
| 1 Month Change | -0.068% |
| 3 Month Change | 11.21% |
| 1 Year Change | 19.54% |
| 3 Year Change | 96.26% |
| 5 Year Change | 140.26% |
| Change since IPO | -75.70% |
Recent News & Updates
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn
Feb 14
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23Merrimack Pharmaceuticals GAAP EPS of -$0.04
Aug 04Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19Recent updates
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn
Feb 14Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23Merrimack Pharmaceuticals GAAP EPS of -$0.04
Aug 04Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
May 19Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?
Feb 22Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business
Jan 01Merrimack Pharma jumps 42% on bullish timeline for potential Onivyde milestone payment
Dec 02Merrimack Pharmaceuticals reports Q3 results
Nov 05Shareholder Returns
| MACK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.3% | -4.7% | -3.7% |
| 1Y | 19.5% | -2.7% | 20.2% |
Return vs Industry: MACK exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: MACK matched the US Market which returned 20.5% over the past year.
Price Volatility
| MACK volatility | |
|---|---|
| MACK Average Weekly Movement | 2.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MACK has not had significant price volatility in the past 3 months.
Volatility Over Time: MACK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Gary Crocker | www.merrimack.com |
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals, Inc. Fundamentals Summary
| MACK fundamental statistics | |
|---|---|
| Market cap | US$213.33m |
| Earnings (TTM) | -US$1.18m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-180.6x
P/E RatioIs MACK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MACK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.18m |
| Earnings | -US$1.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.081 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MACK perform over the long term?
See historical performance and comparison